Can you stay on a low dose of Mounjaro long-term?

The myth: you have to keep going up until you hit the highest dose

This is one of the most common misunderstandings about Mounjaro, and it is worth correcting plainly. The titration schedule in the prescribing guidance is a ceiling, not a conveyor belt. Tirzepatide is licensed in the UK in six strengths (2.5, 5, 7.5, 10, 12.5 and 15mg) and the SmPC describes a typical upward progression in roughly four-week steps. But the purpose of that schedule is tolerability, not ambition. You begin at 2.5mg so your digestive system has time to settle. After that, the direction of travel is a prescriber's call, made dose by dose, taking into account how you feel and how your weight is tracking.

Many patients reach a point where they are losing weight steadily, tolerating the medicine comfortably, and see no clinical reason to increase. Staying put is a legitimate outcome, not a failure to comply. The full picture on Mounjaro, including how its dual GIP and GLP-1 mechanism works, explains why the medicine can be effective at a range of doses rather than only at the maximum.

The key clinical principle is that the lowest effective dose is generally the preferred one. Side effects are often dose-related, so remaining at a strength that works well for you is a reasonable and evidence-informed approach. If you are wondering whether that could mean staying at the starting strength long-term, we have written in detail about whether remaining on 2.5mg of Mounjaro is a clinically reasonable option, which is worth reading before assuming you must move up.

When staying at 2.5mg or 5mg might genuinely be appropriate

The 2.5mg pen is described in the SmPC as a starter dose, but that framing occasionally misleads people into thinking it has no therapeutic value. For some individuals (particularly those who are highly sensitive to GI side effects) 2.5mg does produce a meaningful reduction in appetite and, over time, measurable weight change. It is not the norm, but it happens. Our prescribers are familiar with the question, and if you want a more detailed look at what staying on 2.5mg Mounjaro involves in practice, that guidance sets out the clinical considerations clearly. Our prescribers are familiar with the question; if you are wondering specifically about whether 5mg could be a sustainable long-term dose, that is a real conversation worth having rather than assuming the answer is no.

At 5mg and 7.5mg, the evidence for meaningful weight loss is clearer. SURMOUNT-1, published in the New England Journal of Medicine, showed significant average weight reduction across all active dose arms, not just the 15mg group. The highest doses produced the greatest average loss, but that does not mean lower doses produced none. The broader context of weight-loss treatment matters here: a steady, well-tolerated result at a moderate dose may suit someone better than chasing a larger number at the cost of persistent nausea or disrupted daily life.

If you find yourself mid-prescription wondering whether your current dose is still working (or whether there is any point increasing) that is exactly the kind of thing to raise with your prescriber before your next pen is due rather than making a change unilaterally.

What happens if you stop titrating and your weight plateaus

This is where the clinical conversation gets more nuanced. NICE's appraisal of tirzepatide (NICE TA1026) includes guidance that if a patient has not achieved at least 5% weight loss after six months at the highest tolerated dose, continuing treatment should be reviewed. That six-month review point is relevant regardless of which dose you have reached.

The phrase "highest tolerated dose" is important. It is not "highest possible dose", it means the dose your body can sustain without unacceptable side effects. If 7.5mg is your ceiling because 10mg brought persistent nausea, then 7.5mg is your highest tolerated dose, and the review applies at that level. For specific questions about staying at 7.5mg long-term, the same logic applies: it is a prescriber assessment, not a rule written in advance.

Weight plateaus are common on any weight-loss medicine and do not automatically mean a dose increase is needed. Lifestyle factors, stress, and the natural slowing of the body's response over time all play a part. A good prescriber will look at the whole picture rather than defaulting to "increase the dose" as the only lever.

Dose decisions at nume are made by a real clinician, not an automated system

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation and every repeat order. Nobody is auto-approved, and dose changes are not triggered by a click-through on a form. If you are thinking about whether your current dose is right (or want to understand what staying on it long-term would involve) our prescribers are the right people to ask. You can read about common questions we answer or, if you have a specific concern, get in touch with our team directly.

It is also worth being clear on cost: the price of Mounjaro in the UK varies by dose and provider, so patients sometimes ask whether staying on a lower dose is cheaper. That is a fair practical question. What we would say is that the dose question should always be answered on clinical grounds first, with cost as a secondary consideration, not the other way around.

If you are not yet a patient and are thinking about whether Mounjaro might suit you, the right first step is a consultation. Speak to our prescribers through a free consultation, reviewed the same day, with no waiting list and no obligation to proceed.